Share on StockTwits

Bruker (NASDAQ:BRKR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Monday. They currently have a $25.40 price target on the stock. Zacks‘s target price would indicate a potential upside of 22.82% from the company’s current price.

Shares of Bruker (NASDAQ:BRKR) traded down 3.00% on Monday, hitting $20.06. The stock had a trading volume of 858,656 shares. Bruker has a one year low of $17.75 and a one year high of $24.93. The stock’s 50-day moving average is $23.45 and its 200-day moving average is $22.20. The company has a market cap of $3.362 billion and a price-to-earnings ratio of 45.05.

Bruker (NASDAQ:BRKR) last announced its earnings results on Wednesday, August 6th. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.19 by $0.02. The company had revenue of $457.40 million for the quarter, compared to the consensus estimate of $457.90 million. During the same quarter last year, the company posted $0.18 earnings per share. Bruker’s revenue was up .5% compared to the same quarter last year. On average, analysts predict that Bruker will post $0.81 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. initiated coverage on shares of Bruker in a research note on Thursday, July 17th. They set a “buy” rating on the stock. Separately, analysts at ISI Group downgraded shares of Bruker from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $25.50 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Bruker from $25.00 to $27.50 in a research note on Tuesday, July 1st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Bruker has an average rating of “Buy” and an average target price of $25.60.

Bruker Corporation (NASDAQ:BRKR) is a global manufacturer of scientific instruments that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.